title: Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
abstract: OBJECTIVE
  To investigate the effects of dutasteride 0.5 mg once daily for 12 months on lower urinary tract symptoms in treatment-naïve patients with benign prostatic hyperplasia.
  
  
  METHODS
  The present open-label, single-center, prospective study recruited 105 outpatients. International Prostate Symptom Score, Overactive Bladder Symptom Score, quality of life score testing and Benign Prostatic Hyperplasia Impact Index were used for assessing subjective symptoms. Urodynamic study including uroflowmetry, cystometry and pressure flow study were carried out to evaluate objective symptoms. As parameters of storage function, first desire to void, maximum cystometric capacity and occurrence of involuntary detrusor contraction were measured, whereas maximum flow rate, detrusor pressure at maximum flow rate, post-void residual urine and bladder outlet obstruction index were assessed as parameters of voiding function. Wilcoxon's rank-sum test, Student's t-test and the χ(2)-test were carried out to evaluate changes in subjective and objective symptoms.
  
  
  RESULTS
  A total of 97 patients with a mean age of 68.8 years and mean prostate volume of 57.6 mL were included in the analysis. Subjective symptom parameters improved significantly after 2 months, and progressively improved until after 12 months. Significant improvements in storage function objective parameters and voiding function objective parameters were observed after 6 months, and further improvements were obtained after 12 months.
  
  
  CONCLUSIONS
  Dutasteride is effective in relieving lower urinary tract symptoms by improving storage and voiding function, as well as subjective symptoms in patients with benign prostatic hyperplasia.
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: Momokazu
authors.initials: M
authors.lastname: Gotoh
authors.forename: Masashi
authors.initials: M
authors.lastname: Kato
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Funahashi
authors.forename: Michiro
authors.initials: M
authors.lastname: Narita
authors.forename: Kotoko
authors.initials: K
authors.lastname: Mitsui
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D001378:Azasteroids / Q000494:pharmacology / Q000627:therapeutic use*; D000068538:Dutasteride; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications*; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D000068538:Dutasteride
keywords: benign prostatic hyperplasia; lower urinary tract symptoms; urodynamics